On the stock market since 2004, it operates in the world of health and science. It has 4,526 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 5% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $476.2M in the vault; even if every debt were paid off, $28.7M would remain.
The average analyst price target is $3.00 — 55% above today’s price.
It pays out $0.57 per share each year — regular cash for whoever holds the stock.
A loss of $99.4M against $757.3M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, EVO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EVO has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.